Plus Therapeutics (NASDAQ:PSTV) Trading Down 3% – Time to Sell?

Plus Therapeutics, Inc. (NASDAQ:PSTV)’s stock price traded down 3% during trading on Friday . The stock traded as low as $0.35 and last traded at $0.37. 7,236,419 shares were traded during mid-day trading, a decline of 32% from the average session volume of 10,685,241 shares. The stock had previously closed at $0.38.

Analyst Ratings Changes

Several equities research analysts have recently commented on the company. Ascendiant Capital Markets upped their price objective on Plus Therapeutics from $20.00 to $20.50 and gave the stock a “buy” rating in a research note on Thursday, June 5th. HC Wainwright reduced their price objective on Plus Therapeutics from $5.50 to $3.00 and set a “buy” rating for the company in a research note on Friday, June 27th. D Boral Capital lowered Plus Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Monday, May 5th. Finally, D. Boral Capital restated a “hold” rating and issued a $9.00 price objective on shares of Plus Therapeutics in a research note on Wednesday, June 25th.

Plus Therapeutics Trading Down 3.0%

The firm has a market cap of $18.95 million, a PE ratio of -0.13 and a beta of 0.69. The stock has a 50 day simple moving average of $0.34 and a 200-day simple moving average of $0.77.

Plus Therapeutics (NASDAQ:PSTV) last issued its quarterly earnings results on Friday, May 30th. The company reported ($0.56) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.39). The business had revenue of $1.06 million during the quarter, compared to analyst estimates of $1.11 million. On average, equities research analysts expect that Plus Therapeutics, Inc. will post -2.3 EPS for the current year.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Plus Therapeutics stock. Virtu Financial LLC purchased a new stake in Plus Therapeutics, Inc. (NASDAQ:PSTV) in the first quarter, according to the company in its most recent disclosure with the SEC. The firm purchased 40,030 shares of the company’s stock, valued at approximately $38,000. Virtu Financial LLC owned about 0.24% of Plus Therapeutics at the end of the most recent quarter. 3.28% of the stock is currently owned by hedge funds and other institutional investors.

Plus Therapeutics Company Profile

Plus Therapeutics, Inc, a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. Its lead radiotherapeutic drug candidate is rhenium (186Re) obisbemeda, a patented radiotherapy that targets central nervous system cancers and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers.